Evidence map›Paper›PMID 31054001›Full record

ArticleMolecular imaging and biology2020

Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.

Naoki Nishio, Nynke S van den Berg, Stan van Keulen, Brock A Martin, Shayan Fakurnejad, Quan Zhou, Guolan Lu, Stefania U Chirita, Michael J Kaplan, Vasu Divi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Trial
  2. Fluorescent Molecular Imaging Can Improve Intraoperative Sentinel Margin Detection in Oral Squamous Cell Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Intraoperative fluorescence in solid head and neck cancer: A scoping review.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. High-precision tumor resection down to few-cell level guided by NIR-IIb molecular fluorescence imaging.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Naoki NishioDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, 875 Blake Wilbur Drive, Palo Alto, CA, 94304, USA.
Nynke S van den BergDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, 875 Blake Wilbur Drive, Palo Alto, CA, 94304, USA.
Stan van KeulenDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, 875 Blake Wilbur Drive, Palo Alto, CA, 94304, USA.
Brock A MartinDepartment of Pathology, Stanford University, Stanford, CA, USA.
Shayan FakurnejadDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, 875 Blake Wilbur Drive, Palo Alto, CA, 94304, USA.
Quan ZhouDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, 875 Blake Wilbur Drive, Palo Alto, CA, 94304, USA.
Guolan LuDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, 875 Blake Wilbur Drive, Palo Alto, CA, 94304, USA.
Stefania U ChiritaDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, 875 Blake Wilbur Drive, Palo Alto, CA, 94304, USA.
Michael J KaplanDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, 875 Blake Wilbur Drive, Palo Alto, CA, 94304, USA.
Vasu DiviDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, 875 Blake Wilbur Drive, Palo Alto, CA, 94304, USA.
Alexander D ColevasDepartment of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA, USA.
Eben L RosenthalDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, 875 Blake Wilbur Drive, Palo Alto, CA, 94304, USA. elr@stanford.edu.

Funding

Stanford Molecular Imaging Scholars (SMIS) ProgramT32CA118681 · NCI · STANFORD UNIVERSITY · PI CRAIG S LEVIN · 2016 to 2026
$4.3M
Prototype optical device for image guided surgery with panitumumab-IRDye800R01CA190306 · NCI · STANFORD UNIVERSITY · PI ROSENTHAL, EBEN L. · 2015 to 2019
$2.6M
NCI NIH HHS R01 CA190306NCI NIH HHS T32 CA118681
6 · The paper itself

Abstract

purposeTo identify the optimal dosing strategy for fluorescence-guided surgery in patients with head and neck squamous cell carcinoma, we conducted a dose-ranging study evaluating the anti-epidermal growth factor receptor (EGFR) therapeutic antibody, panitumumab, that was fluorescently labeled with the near-infrared dye IRDye800CW. PROCEDURES: Patients (n = 24) received either 0.5 or 1.0 mg/kg panitumumab-IRDye800CW in the weight-based dosing group or 25 or 50 mg panitumumab-IRDye800CW in the fixed dosing group. Following surgery, whole primary specimens were imaged in a closed-field device and the mean fluorescence intensity (MFI) and tumor-to-background ratio (TBR) were assessed. Clinical variables, including dose, time of infusion-to-surgery, age, unlabeled dose, gender, primary tumor site, and tumor size, were analyzed to evaluate the factors affecting the fluorescence intensity in order to identify the optimal dose for intraoperative fluorescence imaging.

resultsA total of 24 primary tumor specimens were imaged and analyzed in this study. Although no correlations between TBR and dose of panitumumab-IRDye800CW were found, there were moderate-strong correlations between the primary tumor MFI and panitumumab-IRDye800CW dose for fixed dose (mg) (R

conclusionsAntibody-based imaging for surgical resection is under investigation in multiple clinical trials. Our data suggests that a fixed dose of 50 mg is an appropriate diagnostic dose for successful surgical fluorescence imaging.

Indexed as

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalBenzenesulfonatesDose-Response Relationship, DrugErbB ReceptorsFemaleFluorescent DyesHead and Neck NeoplasmsHumansImmunoconjugatesIndolesMaleMiddle AgedNon-Randomized Controlled Trials as TopicOptical ImagingPanitumumabAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalBenzenesulfonatesErbB ReceptorsFluorescent DyesImmunoconjugatesIndolesIRDye 800CWPanitumumabEGFRFluorescenceHead and neck cancerImage-guided surgeryIRDye800CWNear-infrared imagingOptimal dosing strategyPanitumumab

Identifiers

PMID31054001
PMCPMC7017887

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.